New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Alnylam Pharmaceuticals, Inc.
ALNY
Shape
US Flag

NASDAQ

EPS improving

EPS improving

37B

Biotechnology

Next Earning date - 31 Oct 2024

37B

Biotechnology

Next Earning date - 31 Oct 2024

284.86USD
Shape-8.83 ( -3.01%)
favorite-chart

Relative Strenght

24
favorite-chart

Volume Buzz

40%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

6%

Quote Panel

Shape
Updated October 27, 2024
1W -2.45 % 1M 3.57 % 3M 20.56 % 1Y 88.14 %

Key Metrics

Shape
  • Market Cap

    36.57B


  • Shares Outstanding

    128.38M


  • Share in Float

    127.23M


  • Dividende

    0


  • Earning Date

    31 Oct 2024


  • Price Target

    284.86


  • Average Volume

    832084


  • Beta

    0.381


  • Range

    141.98-304.39


  • Industry

    Biotechnology


  • Website

    https://www.alnylam.com


  • Sector

    Healthcare


Fundamentals

Shape

633.02x

P/E Ratio

15.60x

P/S Ratio

-11770.84x

P/B Ratio

-805.0

Debt/Equity

-3.1%

Net Margin

$-0.6

EPS

How ALNY compares to sector?

P/E Ratio

Relative Strength

Shape

ALNY

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$3B

Shape286%

2025-Revenue

$1.57

Shape-1110%

2025-EPS

$2B

Shape-3167%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Goldman Sachs

upgrade

Previous: Neutral

2024-08-16

Now: Buy

JMP Securities

initialise

Previous: Not converted

2024-04-08

Now: Positive

Goldman Sachs

downgrade

Previous: Not converted

2024-02-16

Now: Neutral

BMO Capital

upgrade

Previous: Market Perform

2023-05-05

Now: Outperform

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-3.32
vs -1.72

Q4.22

arrow
arrow

N/A

-1.68
vs -2.16

Q1.23

arrow
arrow

N/A

-1.40
vs -2.00

Q2.23

arrow
arrow

N/A

-2.21
vs -2.29

Q3.23

arrow
arrow

+135%

1.15
vs -3.32

Q4.23

arrow
arrow

N/A

-1.10
vs -1.68

Q1.24

arrow
arrow

N/A

-0.16
vs -1.40

Q2.24

arrow
arrow

+125%

0.56
vs -2.21

Q3.24

arrow
arrow

N/A

-0.91
vs 1.15

Q4.24

arrow
arrow

N/A

-0.85
vs -1.10

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+41%

264.3M  vs 187.6M

Q4.22

arrow
arrow

+30%

335M  vs 258.5M

Q1.23

arrow
arrow

+50%

319.3M  vs 213.3M

Q2.23

arrow
arrow

+42%

318.8M  vs 224.8M

Q3.23

arrow
arrow

+184%

750.5M  vs 264.3M

Q4.23

arrow
arrow

+31%

439.7M  vs 335M

Q1.24

arrow
arrow

+55%

494.3M  vs 319.3M

Q2.24

arrow
arrow

+107%

659.8M  vs 318.8M

Q3.24

arrow
arrow

-29%

533.1M  vs 750.5M

Q4.24

arrow
arrow

+27%

558.5M  vs 439.7M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+600%

6
vs -1.58

Q4.22

arrow
arrow

+131%

1.31
vs 6

Q1.23

arrow
arrow

+67%

0.67
vs 1.31

Q2.23

arrow
arrow

+68%

0.68
vs 0.67

Q3.23

arrow
arrow

-89%

-0.89
vs 0.68

Q4.23

arrow
arrow

+62%

0.62
vs -0.89

Q1.24

arrow
arrow

+30%

0.3
vs 0.62

Q2.24

arrow
arrow

+551%

5.51
vs 0.3

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

516

516
vs 454

14%

Q4.22

arrow
arrow

514

514
vs 516

0%

Q1.23

arrow
arrow

497

497
vs 514

-3%

Q2.23

arrow
arrow

492

492
vs 497

-1%

Q3.23

arrow
arrow

493

493
vs 492

0%

Q4.23

arrow
arrow

534

534
vs 493

8%

Q1.24

arrow
arrow

553

553
vs 534

4%

Q2.24

arrow
arrow

571

571
vs 553

3%

Earnings Growth

Latest News